ing new angle to transposon regulation. The relatively low TnsE binding affinity for the β clamp suggests that it has evolved to use the replication factor but not to appropriate it entirely at the expense of other β clamp binding partners and functions. In the wake of the new findings of Parks et al., it is now important to determine how such interactions between transposon proteins and the replication machinery occur, how they are temporally integrated into DNA replication and other processes coordinated by the β clamp, and whether other host proteins are also required.
Although tumor metastases are the cause of death in more than 80% of human cancer patients, the molecular mechanisms underpinning metastasis are still poorly understood. However, one theme that has emerged from recent work is that metastasis involves defects in the molecular machines responsible for epithelial polarity and hence for the epithelial-to-mesenchymal transition (EMT) (Kalluri and Weinberg, 2009) . Epithelial cell polarity is established by multiple cellular processes, including polarized trafficking of cytoskeletal and plasma membrane proteins, the maintenance of a diffusion barrier (tight junctions) (Humbert et al., 2008) , and a 3D organization machinery that integrates extracellular information from receptors, adhesion proteins, and neighboring cells (Tanos and Rodriguez-Boulan, 2008) . Hence, the loss of epithelial polarity during EMT can result from altered regulation of many different signaling pathways, transcription factors, chromatin regulators, and proteins involved in cell adhesion and polarity (Kalluri and Weinberg, 2009; Tanos and Rodriguez-Boulan, 2008) . Indeed, the list of oncogenes and tumor suppressors that modulate cell polarity is long and growing (Humbert et al., 2008; Tanos and Rodriguez-Boulan, 2008) . In recent work, it has been shown that epithelial stem cells may undergo EMT and that EMT induction endows epithelial cells with salient features of stem cells. These cells can also exhibit properties of cancer stem cells upon overexpression of oncogenic Ras (Mani et al., 2008) . In their current work, published in this issue of Cell, Gupta et al. (2009) use these newly discovered attributes of mammary epithelial cells (that is, induction of EMT and stem cell features by defined genetic alterations) to establish a high-throughput screen for compounds that selectively target cancer stem cells.
Gupta et al. use telomerase-immortalized human mammary epithelial (HMLE) cells, in which knockdown of E-cadherin by RNA interference promotes EMT and the acquisition of features typical of cancer stem cells, including high levels of CD44, low levels of CD24, and the capacity to form mammospheres (Figure 1 ). Cells depleted of E-cadherin also show increased resistance to several established tumor chemotherapeutics. In this respect, they resemble human breast carcinoma stem cells that contribute to tumor relapse in vivo. Gupta et al. estab- lish that these cells are ideally suited for a high-throughput, cellular screen for compounds that selectively eliminate cancer stem cells (Figure 1) . The most extensively Breast cancer stem cells: eradication by Differentiation Therapy?
Hartmut Beug 1, * validated hit from their screen is salinomycin, a highly selective potassium ionophore, facilitating bidirectional ion flux (Mitani et al., 1975 Established breast cancer therapies often fail to achieve long-term patient survival, possibly because of tumor relapse as a result of chemotherapyresistant mammary cancer stem cells. Thus, new therapeutic strategies to specifically target these cancer stem cells are urgently required. Gupta et al. (2009) significantly advance this field by presenting the first clear proof of principle that it is feasible to screen for drugs that specifically target breast cancer stem cells. The approach they chose evolved from the concept that normal mammary gland stem cells and cancer stem cells display a highly plastic epithelial phenotype, which allows them to undergo EMT in cell culture (Mani et al., 2008) . It remains unclear, however, by which mechanisms salinomycin selectively targets cells after EMT. Salinomycin is 
salinomycin Targets Breast cancer stem cells
Depicted is the screening approach used by Gupta et al. (2009) . Control human mammary epithelial (HMLE) cells express the basolateral marker E-cadherin and high levels of CD24. These cells do not form mammospheres in suspension culture. In contrast, HMLE cells treated with a short hairpin RNA targeting Ecadherin undergo changes consistent with an epithelial to mesenchymal transition (EMT), including upregulation of the mesenchymal marker vimentin. These cells exhibit features of cancer stem cells, including high levels of CD44 expression and the ability to form mammospheres in suspension culture. These two cell types were then subjected to a high-throughput chemical screen measuring cell viability, which led to the identification of salinomycin as a compound that targets breast cancer stem cells selectively.
used as an antibiotic against eukaryotic parasites in animals and inhibits cartilage degradation during bone development (Peters et al., 2002) . Given that it is a highly selective potassium ionophore, salinomycin may interfere with the function of potassium channels in cancer stem cells. It has been shown that tumor cells express elevated levels of various types of K + channels. Their overexpression enhances proliferation, and drugs acting as channel blockers inhibit cell proliferation (Le Guennec et al., 2007; Zhang et al., 2009) . Perhaps more importantly, certain K + channels regulate migration. In a similar vein, certain G protein-coupled K + channels are overexpressed in breast cancer lymph node metastases (Zhang et al., 2009) . Given the importance of the cell polarity machinery to cell migration (Etienne-Manneville, 2008) , it is tempting to speculate that K + channels targeted by salinomycin have a critical function in epithelial polarity and metastasis, which can be deregulated by salinomycin.
In plants, the juvenile and adult phases of vegetative development can be distinguished by leaf morphology, and the reproductive phase of development can be distinguished by the production of flowers. SQUAMOSA PROMOTER BIND-ING-LIKE (SPL) transcription factors are regulated by the microRNA miR-156 and influence the transitions between these developmental phases (Schwab et al., 2005; Wu and Poethig, 2006) . Intricate models have been proposed to explain the regulation of the developmental transitions between these phases, particularly between the adult vegetative and reproductive phases (Baurle and Dean, 2006 The involvement of SPL transcription factors in the vegetative phase transition first became clear by studying miR-156, a microRNA whose overexpression prolongs the juvenile phase in both maize and the model plant Arabidopsis thaliana (Wu and Poethig, 2006; Chuck et al., 2007) . The miR-156 microRNA represses the activity of 10 of the 16 SPL transcription factors in Arabidopsis, suggesting that some or all of these proteins promote the transition from the juvenile to the adult phase. In both Arabidopsis and maize, miR-156 expression decreases as the plant ages. Therefore, miR-156 likely acts during the juvenile phase to repress SPL transcription factors and delay the transition to the adult phase; increasing the abundance of SPL transcription factors shortens the juvenile phase and promotes flowering (Wu and Poethig, 2006) . Strikingly, the microRNA miR-172 shows a complementary pattern of expression, that is, low during the juvenile phase and high during the adult phase. In Arabidopsis, miR-172 represses expression of six members of the APETALA2 (AP2)-like family of transcription factors. Two of these transcription factors-TARGET OF
